[go: up one dir, main page]

PE20110808A1 - Anticuerpos contra el receptor 3 de tipo toll - Google Patents

Anticuerpos contra el receptor 3 de tipo toll

Info

Publication number
PE20110808A1
PE20110808A1 PE2011000964A PE2011000964A PE20110808A1 PE 20110808 A1 PE20110808 A1 PE 20110808A1 PE 2011000964 A PE2011000964 A PE 2011000964A PE 2011000964 A PE2011000964 A PE 2011000964A PE 20110808 A1 PE20110808 A1 PE 20110808A1
Authority
PE
Peru
Prior art keywords
section
amino acid
type receiver
identity number
antibodies against
Prior art date
Application number
PE2011000964A
Other languages
English (en)
Inventor
Mark Cunningham
Mateo Lani San
Robert T Sarisky
Raymond Sweet
Robert Rauchenberger
Mark Rutz
Yiqing Feng
Katharine Heeringa
Jinquan Luo
Fang Teng
Alexey Teplyakov
Sheng-Jiun Wu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20110808A1 publication Critical patent/PE20110808A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)

Abstract

SE REFIERE A UN ANTICUERPO O FRAGMENTO DE ESTE QUE SE UNE A UN RESIDUO DE AMINOACIDO DEL RECEPTOR TIPO TOLL 3 (TLR3) EL CUAL COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA DE LA SECCION CON NUMERO DE IDENTIDAD 214; B) UNA REGION VARIABLE DE CADENA LIGERA DE LA SECCION CON NUMERO DE IDENTIDAD 211; C) LAS REGIONES DETERMINATIVAS DE CADENA PESADA COMPLEMENTARIAS (HCDR1, HCDR2 Y HCDR3) DE LAS SECUENCIAS DE AMINOACIDOS COMO LA SECCION CON NUMERO DE IDENTIDAD 70, 77 Y 72; Y D) LAS REGIONES DETERMINATIVAS DE CADENA LIGERA COMPLEMENTARIAS (LCDR1, LCDR2 Y LCDR3) DE LAS SECUENCIAS DE AMINOACIDOS COMO LA SECCION CON NUMERO DE IDENTIDAD 67, 68 Y 78; EN DONDE DICHO ANTICUERPO TIENE UN ISOTIPO IgG4 Y SE CONJUGA CON POLIETILENGLICOL. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA SIENDO UTIL EN EL TRATAMIENTO DE ASMA, RINITIS ALERGICA, ARTRITIS REUMATOIDE
PE2011000964A 2008-10-31 2009-10-30 Anticuerpos contra el receptor 3 de tipo toll PE20110808A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10997408P 2008-10-31 2008-10-31
US16186009P 2009-03-20 2009-03-20
US16510009P 2009-03-31 2009-03-31
US17368609P 2009-04-29 2009-04-29

Publications (1)

Publication Number Publication Date
PE20110808A1 true PE20110808A1 (es) 2011-10-31

Family

ID=42129569

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000964A PE20110808A1 (es) 2008-10-31 2009-10-30 Anticuerpos contra el receptor 3 de tipo toll

Country Status (32)

Country Link
US (8) US8409567B2 (es)
EP (1) EP2350304B1 (es)
JP (1) JP5751631B2 (es)
KR (1) KR101683033B1 (es)
CN (2) CN105601742A (es)
AU (1) AU2009308763B2 (es)
BR (1) BRPI0921696A2 (es)
CA (1) CA2742014A1 (es)
CL (1) CL2011000975A1 (es)
CO (1) CO6362052A2 (es)
CY (1) CY1118797T1 (es)
DK (1) DK2350304T3 (es)
EA (2) EA201500316A1 (es)
EC (1) ECSP11011072A (es)
ES (1) ES2618567T3 (es)
HR (1) HRP20170415T1 (es)
HU (1) HUE031756T2 (es)
IL (1) IL212545A (es)
LT (1) LT2350304T (es)
MX (1) MX2011004635A (es)
MY (1) MY183144A (es)
NI (1) NI201100085A (es)
NZ (2) NZ603824A (es)
PE (1) PE20110808A1 (es)
PL (1) PL2350304T3 (es)
PT (1) PT2350304T (es)
RS (1) RS55861B1 (es)
SI (1) SI2350304T1 (es)
SM (2) SMT201700127T1 (es)
SV (1) SV2011003891A (es)
UA (1) UA109397C2 (es)
WO (1) WO2010051470A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
CN105601742A (zh) 2008-10-31 2016-05-25 詹森生物科技公司 Toll样受体3拮抗剂
US20130090457A1 (en) * 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
MX349056B (es) * 2009-04-29 2017-07-06 Janssen Biotech Inc Antagonistas del receptor tipo toll 3.
AU2010270163B2 (en) 2009-07-10 2016-05-05 Innate Pharma, S.A. TLR3 binding agents
WO2012095432A2 (en) 2011-01-12 2012-07-19 Innate Pharma Tlr3 binding agents
EA201490623A1 (ru) * 2011-09-12 2016-01-29 Янссен Байотек Инк. Антагонисты толл-подобного рецептора 3 для лечения метаболических и сердечно-сосудистых заболеваний
CA2874918A1 (en) 2012-05-31 2013-12-05 Innate Pharma Tlr3 binding agents
JP6366195B2 (ja) * 2013-04-22 2018-08-01 国立大学法人 東京大学 炎症性疾患の予防又は治療剤
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2015016282A1 (ja) * 2013-07-30 2015-02-05 国立大学法人東京大学 放射線誘導性消化管症候群の予防又は治療用医薬組成物
GB201522394D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
CN108884169B (zh) 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
CN109476758B (zh) 2016-06-14 2023-05-23 默沙东有限责任公司 抗-凝血因子xi抗体
WO2018165270A1 (en) * 2017-03-07 2018-09-13 Newtonoid Technologies, L.L.C. Modular elongate wall-mounted sensor system and method
CN109136231B (zh) * 2018-09-14 2019-08-30 苏州大学 一种翘嘴鳜tlr3基因及其应用
US20250312440A1 (en) * 2022-05-31 2025-10-09 The University Of Chicago Chemical screen of modulators for vaccine adjuvants

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
JP2005505284A (ja) * 2001-10-05 2005-02-24 コリー ファーマスーティカル ゲーエムベーハー Ｔｏｌｌ様受容体３シグナリングアゴニストおよびアンタゴニススト
JP2004016021A (ja) 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
US7410975B2 (en) * 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
CA2483732A1 (en) 2004-09-29 2006-03-29 Ronan Le Goffic Toll-like receptor 3, its signalling associated molecule trif and their use thereof
CN101415438B (zh) * 2004-11-30 2013-03-27 森托科尔公司 Toll样受体3拮抗剂、方法和用途
AR051836A1 (es) * 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
WO2007051164A2 (en) 2005-10-27 2007-05-03 Centocor, Inc. Toll like receptor 3 modulators, methods and uses
KR20090130019A (ko) * 2007-03-05 2009-12-17 유타 스테이트 유니버시티 톨-유사 수용체 3(ｔｌｒ３)의 제한적인 작용제
JP2010527633A (ja) * 2007-05-25 2010-08-19 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター及びその使用
EP2334703B1 (en) * 2008-09-17 2015-07-08 Innate Pharma Compositions and methods for detecting tlr3
WO2010040054A2 (en) * 2008-10-02 2010-04-08 Centocor Ortho Biotech Inc. Methods for suppressing toll-like receptor activity
CN105601742A (zh) 2008-10-31 2016-05-25 詹森生物科技公司 Toll样受体3拮抗剂
US20100188778A1 (en) * 2009-01-29 2010-07-29 Castagna Joseph T Disk Drive Assembly Having Flexible Support for Flexible Printed Circuit Board
MX349056B (es) 2009-04-29 2017-07-06 Janssen Biotech Inc Antagonistas del receptor tipo toll 3.
AU2010270163B2 (en) * 2009-07-10 2016-05-05 Innate Pharma, S.A. TLR3 binding agents

Also Published As

Publication number Publication date
PL2350304T3 (pl) 2017-06-30
CN105601742A (zh) 2016-05-25
EA201170636A1 (ru) 2012-03-30
US20140093508A1 (en) 2014-04-03
IL212545A (en) 2014-07-31
US20170058041A1 (en) 2017-03-02
SMT201700127T1 (it) 2017-03-08
KR20110081874A (ko) 2011-07-14
US8409567B2 (en) 2013-04-02
US9255153B2 (en) 2016-02-09
US9932404B2 (en) 2018-04-03
EP2350304B1 (en) 2016-12-14
IL212545A0 (en) 2011-06-30
EA022832B1 (ru) 2016-03-31
US9481731B2 (en) 2016-11-01
CY1118797T1 (el) 2017-07-12
HUE031756T2 (en) 2017-07-28
AU2009308763A1 (en) 2010-05-06
WO2010051470A2 (en) 2010-05-06
ECSP11011072A (es) 2011-06-30
US8540986B2 (en) 2013-09-24
DK2350304T3 (en) 2017-03-13
MY183144A (en) 2021-02-16
SMT201700127B (it) 2017-03-08
US20100166778A1 (en) 2010-07-01
HK1166105A1 (zh) 2012-10-19
PT2350304T (pt) 2017-03-23
NI201100085A (es) 2011-11-21
US20130244281A1 (en) 2013-09-19
CO6362052A2 (es) 2012-01-20
NZ603824A (en) 2013-11-29
LT2350304T (lt) 2017-02-10
US20130280263A1 (en) 2013-10-24
JP5751631B2 (ja) 2015-07-22
CN102300997A (zh) 2011-12-28
HRP20170415T1 (hr) 2017-05-05
AU2009308763B2 (en) 2017-03-09
EP2350304A2 (en) 2011-08-03
MX2011004635A (es) 2011-07-19
US20180179294A1 (en) 2018-06-28
UA109397C2 (uk) 2015-08-25
CA2742014A1 (en) 2010-05-06
RS55861B1 (sr) 2017-08-31
US20110008352A1 (en) 2011-01-13
US20140212426A1 (en) 2014-07-31
NZ592542A (en) 2013-01-25
JP2012507564A (ja) 2012-03-29
EA201500316A1 (ru) 2016-01-29
SV2011003891A (es) 2011-07-21
CN102300997B (zh) 2016-01-20
KR101683033B1 (ko) 2016-12-06
ES2618567T3 (es) 2017-06-21
US9238693B2 (en) 2016-01-19
EP2350304A4 (en) 2014-04-16
CL2011000975A1 (es) 2012-02-03
US9522957B2 (en) 2016-12-20
SI2350304T1 (sl) 2017-04-26
BRPI0921696A2 (pt) 2015-08-18

Similar Documents

Publication Publication Date Title
PE20110808A1 (es) Anticuerpos contra el receptor 3 de tipo toll
PE20081503A1 (es) Miembros de union para il-6
PE20220218A1 (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20191408A1 (es) Proteinas de union a antigeno st2
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20090688A1 (es) MIEMBROS DE UNION PARA LAS MOLECULAS DE IgE
PE20121360A1 (es) Anticuerpos neutralizadores contra el receptor de prolactina
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20091351A1 (es) Anticuerpos humanizados especificos para el factor von willebrand
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
PE20141706A1 (es) Anticuerpos de union a trombina y usos del mismo
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20150002A1 (es) Anticuerpos anti-fcrn

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed